ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Fresenius Kabi Named 2023 Supplier Partner of the Year by Vizient

Recognition Based on Commitment to Collaboration, Quality and Service

Fresenius Kabi has been named the 2023 Supplier Partner of the Year by Vizient, Inc., the nation’s largest provider-driven health care performance improvement company. The recognition was celebrated September 18-21 at the 2023 Vizient Connections Summit in Las Vegas.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231003375800/en/

Fresenius Kabi Named 2023 Supplier Partner of the Year by Vizient. (Graphic: Business Wire)

Fresenius Kabi Named 2023 Supplier Partner of the Year by Vizient. (Graphic: Business Wire)

According to Vizient, the Supplier Partner of the Year demonstrates an unmatched willingness to improve performance and deliver on Vizient’s mission to strengthen Vizient provider customers’ delivery of high-value care. With actively engaged senior executives, the Supplier Partner of the Year provides comprehensive contract access across product/service lines and participates widely in performance improvement solutions and programs, proactively engaging the broader Vizient enterprise and bringing high-value solutions to unmet market needs.

“This recognition as Vizient’s Supplier Partner of the Year reflects our team’s commitment to collaboration and innovation to enhance quality of care and patient safety while controlling costs,” said Scott Meacham, president, Pharmaceuticals at Fresenius Kabi USA. “At every level of our organization, we are focused on helping customers find new solutions for meeting the challenges of today’s health care environment.”

The award marks the second time Fresenius Kabi has been named Supplier Partner of the Year since 2016. In addition, Fresenius Kabi has been named Vizient’s Pharmaceutical Partner of the Year three times, and twice as the Vizient Strategic Programs Pharmaceutical Supplier of the Year in this time period.

“We are excited to recognize Fresenius Kabi as this year’s winner of the prestigious Supplier Partner of the Year Award. Fresenius Kabi has demonstrated how suppliers can work differently with Vizient to ensure that together we are delivering on our provider customer’s holistic needs relative to cost, quality, and market performance. They have also shown exemplary commitment to quality and service, putting providers and the patients they care for at the center of all they do,” said Simrit Sandhu, executive vice president, clinical supply solutions, Vizient.

About Fresenius Kabi

Fresenius Kabi (www.fresenius-kabi.com/us) is a global health care company that specializes in injectable medicines, biosimilars, and technologies for infusion, transfusion, and clinical nutrition. The company’s products and services are used to help care for patients with critical and chronic conditions. The company’s U.S. headquarters is in Lake Zurich, Illinois. The company’s global headquarters is in Bad Homburg, Germany. To learn about U.S. career opportunities at Fresenius Kabi, visit us at www.fresenius-kabi.com/us/join-us and follow us on LinkedIn.

#FreseniusKabi has been named the 2023 Supplier Partner of the Year by @VizientInc, the nation’s largest provider-driven #healthcare performance improvement company.

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  244.41
+1.37 (0.56%)
AAPL  268.47
-1.30 (-0.48%)
AMD  233.54
-4.16 (-1.75%)
BAC  53.20
-0.09 (-0.17%)
GOOG  279.70
-5.64 (-1.98%)
META  621.71
+2.77 (0.45%)
MSFT  496.82
-0.28 (-0.06%)
NVDA  188.15
+0.07 (0.04%)
ORCL  239.26
-4.54 (-1.86%)
TSLA  429.52
-16.39 (-3.68%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.